QuidelOrtho Corp

QuidelOrtho Corp develops and markets diagnostic testing products used to detect, monitor, and help manage disease across clinical and decentralized care settings. Its portfolio spans immunoassay, molecular testing, clinical chemistry, transfusion medicine, and point-of-care systems, with sales and operations across the United States and a global network serving more than 140 countries and territories.

−17,5 %

−41,5 %

−1,9 %

1.50

0.90

— QuidelOrtho Corp
%
Point of Care35% Rapid diagnostic systems and assays used at or near the patient.
Labs25% Central laboratory diagnostic instruments, reagents, and workflows.
Transfusion Medicine20% Immunohematology and donor screening products for blood banks.
Molecular Diagnostics15% Molecular tests and related platforms for infectious disease and other uses.
Non-core revenue5% Contract manufacturing and business collaborations outside core product sales.

QuidelOrtho sells to a mix of direct end users and distributors serving hospitals, clinical laboratories, physician...

  • Distributorsprimary

    Buy and resell diagnostic products into multiple healthcare channels; important for reach in fragmented markets.

  • Hospitals and clinical laboratoriesprimary

    Purchase lab and molecular diagnostics for routine and specialized testing workflows.

  • Physician offices and urgent care clinicsprimary

    Buy rapid point-of-care tests for fast clinical decisions at the site of care.

  • Blood banks and donor centerssecondary

    Use transfusion medicine and donor screening products to support blood safety and compatibility testing.

  • Retail and OTC end userssecondary

    Buy selected consumer-facing tests for self-use or retail screening applications.

QuidelOrtho operates globally, with manufacturing facilities in the U.S., U.K., and China and commercial support across...

  • •Manufacturing in the U.S., U.K. and China
  • •Commercial reach across more than 140 countries and territories
  • •North America and Western Europe are served primarily through direct sales
  • •China, Asia Pacific, Middle East, Africa, Eastern Europe and Latin America use mixed channels
  • •Regional sales and service centers support local customer coverage
  • •Primary distribution centers are located in North America and Europe

QuidelOrtho’s strategy centers on broadening its diagnostic portfolio, supporting customers with direct service and...

01
Broaden and support the core diagnostic portfoliomedium-term

A wider test menu helps retain customers and cross-sell across care settings.

02
Maintain strong commercial coverage by regionshort-term

Channel mix must fit local market structure, especially in fragmented markets.

03
Protect supply reliability and manufacturing flexibilitymedium-term

Diagnostic customers depend on consistent product availability and quality.

QuidelOrtho faces competition across multiple diagnostic categories, and demand can be concentrated in a small number...

high

Customer and distributor concentration

A small number of distributors and direct customers account for a meaningful share of revenue.

Scope
Loss of a key distributor or customer could reduce sales and market access.
Materiality
high
high

Respiratory testing demand volatility

A significant portion of revenue comes from respiratory products, including COVID-19 and flu tests.

Scope
Demand can fall quickly as infection rates, testing behavior, and reimbursement change.
Materiality
high
high

Supply chain and manufacturing disruption

The company relies on raw materials, components, and multi-country manufacturing.

Scope
Interruptions can affect product availability, service levels, and customer retention.
Materiality
high
high

Goodwill impairment

Reporting unit fair values depend on revenue growth, margins, discount rates, and market multiples.

Scope
Non-cash charges can be large when market capitalization or forecasts decline.
Materiality
high
medium

Competitive pressure

The diagnostics market is highly competitive across point-of-care, lab, and molecular testing.

Scope
Competition can affect pricing, product launches, and distributor relationships.
Materiality
high
Goodwill impairment
Can produce large non-cash charges when market value or outlook weakens
Revenue concentration and channel mix
Quarterly results can vary with respiratory demand and distributor ordering patterns
Non-core revenue and collaboration accounting
Can affect mix, margins and comparability across periods
Legal and contract-related accruals
These items can materially affect operating expense and earnings in a given year

QUEST DIAGNOSTICS INC

DGX · Services-Medical Laboratories

Quanterix Corp

QTRX · Laboratory Analytical Instruments

Insight Molecular Diagnostics Inc.

IMDX · In Vitro & In Vivo Diagnostic Substances

REVVITY, INC.

RVTY · Laboratory Analytical Instruments

Longduoduo Co Ltd

LDDD · Services-Health Services

AddLife

ALIF-B.ST · Health Care

: 29/04/2026